Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. (Q30350675)

20 June 2017

1 reference

title

Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. (English)

1 reference

20 June 2017

0 references

1 reference

Eitan Kerem

1 reference

20 June 2017

publication date

1 September 2005

1 reference

20 June 2017

published in

Pediatric Pulmonology

1 reference

20 June 2017

1 reference

20 June 2017

1 reference

20 June 2017

page(s)

183-196

1 reference

The cystic fibrosis transmembrane conductance regulator gene

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

The spectrum of cystic fibrosis mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

Five Percent of Normal Cystic Fibrosis Transmembrane Conductance Regulator mRNA Ameliorates the Severity of Pulmonary Disease in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.20200

21 January 2018

Identifiers

DOI

10.1002/PPUL.20200

1 reference

20 June 2017

1 reference